AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Insilico Medicine vs Schrödinger

Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.

VS
Insilico Medicine official logo and brand icon

Insilico Medicine

Enterprise
Visit WebsiteFull Review
Schrödinger official logo and brand icon

Schrödinger

Enterprise
Visit WebsiteFull Review

Verdict by Category

AI content generation failed. Refresh the page to try again.
View Insilico Medicine View Schrödinger
Feature & Spec Matrix

Detailed Comparison25 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Insilico Medicine
Insilico Medicine
Schrödinger
Schrödinger
Pricing Model
EnterpriseCustom Enterprise Biotech / Pharma Licensing for PandaOmics, Chemistry42, and inClinico — Partnership inquiry
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free access — platform licensing and drug discovery collaborations via enterprise agreements
Academic licensing available at reduced rates; commercial pricing via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical companies and biotechs seeking to accelerate drug discovery from target identification to clinical prediction using generative AI and automated chemistry
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Enterprise & Scalability
Difference
Pharma.AI platform available for licensing and collaboration agreements with major pharma companies; HKEX listed (3696); regulatory filings in multiple jurisdictions; automated robotic lab integration; multi-country R&D centers
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Pharma.AI end-to-end platform: PandaOmics (target ID), Chemistry42 (molecule design), InClinico (clinical prediction)
Supported
Supported
Rentosertib (ISM001-055) — world's most advanced fully AI-discovered drug in Phase 3 for IPF
Difference
Insilico Medicine Advantage
Not listed
31+ drug programs across 29 targets in cancer, fibrosis, CNS, immunity, and aging
Difference
Insilico Medicine Advantage
Not listed
Generative AI for de novo molecule design against novel and known drug targets
Difference
Insilico Medicine Advantage
Not listed
Automated robotic laboratory in Suzhou connected directly to the AI platform
Difference
Insilico Medicine Advantage
Not listed
300+ patents filed, 200+ peer-reviewed publications in top scientific journals
Difference
Insilico Medicine Advantage
Not listed
Multi-billion dollar licensing partnerships with Sanofi, Fosun Pharma, and Exelixis
Supported
Supported
Chemistry42 generative AI designs novel molecules not found in existing chemical libraries
Difference
Insilico Medicine Advantage
Not listed
PandaOmics AI for target identification using multi-omics, literature, and clinical data
Difference
Insilico Medicine Advantage
Not listed
Listed on Hong Kong Stock Exchange (HKEX: 3696) — founded 2014 at Johns Hopkins University
Difference
Insilico Medicine Advantage
Not listed
Physics-based molecular simulation: Maestro, Glide, Jaguar, Prime, and FEP+ for drug and materials discovery
Difference
Not listed
Schrödinger Advantage
Bunsen AI co-scientist (July 2026) for hypothesis generation, experiment design, and molecular insight
Difference
Not listed
Schrödinger Advantage
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Not listed
Schrödinger Advantage
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Not listed
Schrödinger Advantage
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Not listed
Schrödinger Advantage
$255.87M revenue in 2025 with 23% growth — NASDAQ listed (SDGR)
Difference
Not listed
Schrödinger Advantage
500+ enterprise customers including top 20 global pharma companies
Difference
Not listed
Schrödinger Advantage
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Not listed
Schrödinger Advantage
Insilico Medicine icon

Insilico Medicine Pros & Cons

Pros

  • World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
  • End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
  • 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
  • Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
  • Automated robotic lab in Suzhou closing the loop between AI design and physical testing
  • Global presence: US, China, Canada, Middle East — with partnerships across big pharma
  • Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing

Cons

  • Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
  • Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
  • Dual-track model (platform + internal pipeline) adds operational complexity
  • Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
  • Listed on HKEX (Hong Kong) — less accessible to US institutional investors
Schrödinger icon

Schrödinger Pros & Cons

Pros

  • 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
  • Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
  • FEP+ delivers industry-leading accuracy in binding affinity prediction
  • NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
  • 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
  • Materials science applications extend reach to battery, semiconductor, and chemical sectors
  • Cloud-hosted subscriptions eliminate on-premise infrastructure burden

Cons

  • Software is expensive — enterprise pricing puts it out of reach for smaller labs
  • Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
  • Drug discovery segment revenue is milestone-dependent and lumpy
  • Platform learning curve is steep without computational chemistry background
  • Competition from newer, purely AI-native platforms is intensifying
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Insilico Medicine vs DAX Copilot Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Insilico Medicine and DAX Copilot in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare